FULC Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.94
- P/S (TTM)
- 2.66
- EV/EBITDA
- -3.10
Profitability & growth
- ROE (TTM)
- -32.4%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 2.58
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Fulcrum Therapeutics Inc
Company profileFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
